Medical Marijuana Inc.’s (OTCMKTS:MJNA) Subsidiary Announces Encouraging Validcare Study Results on CBD Liver Toxicity

Medical Marijuana Inc (OTCMKTS:MJNA) has announced that its Kannaway® subsidiary, which participated in the Validcare clinical trial, has announced encouraging results. The trial used Kannaway®’s hemp-derived CBD products as part of the initiative to meet the FDA’s request for data on utilization of botanical cannabidiol regarding potential liver toxicity issues.

Validcare study shows no liver toxicity

Validcare principal investigators indicated that the trial didn’t show any evidence of liver toxicity in the 839 study subjects who orally took hemp-derived CBD for at least 60 days. Most importantly, the investigators met with the FDA Cannabis Product council on March 15 to share the results and answer the agency’s March 5, 2021 request for science-based evidence to determine the ideal regulatory path for hemp-CBD products. During the study, blood markers for AST (Aspartate Aminotransferase), ALT (Alanine Aminotransferase), Bilirubin, and ALP (alkaline Phosphatase) levels were examined.

Stuart Titus, the company’s CEO, said that the study findings validate what they have been doing in Brazil and Mexico to study the efficacy and safety of CBD. He added that they are optimistic that they will continue participating in similar future studies to expand access to premium botanical products. Titus said that he was delighted to see participating stakeholders with long-term vision coming together for industry-wide progress that will benefit end consumers. Medical Marijuana is conducting similar research in Europe in partnership with the European Industrial Hemp Association.

Brands offered funding and product

The brands that took part in the study offered funding, authenticity certificates, products, and helps with adult US-based user recruitment. Using Validcare’s decentralized clinical research platform and collaboration with national labs enabled the principal investigators and participants to successfully finalize the first cohort and compile and deliver results to the FDA and brands in six weeks despite its impact pandemic.

Kannaway CEO Blake Schroeder said that they are proud as creators of the first testing measures for the whole CBD industry. He equally said that they are delighted to offer premium and safe products in the market.

Related Posts

About The Author

Add Comment